An institutional review of treatment outcomes in extraosseous Ewing's sarcoma- the largest Asian experience

Ewing, 1972, Classics in oncology. Diffuse endothelioma of bone. James Ewing. Proceedings of the New York Pathological Society, 1921, CA Cancer J Clin, 22, 95, 10.3322/canjclin.22.2.95 Chakraborty, 2018, Trends in incidence of Ewing sarcoma of bone in India - Evidence from the National Cancer Registry Programme (1982-2011), J Bone Oncol, 12, 49, 10.1016/j.jbo.2018.04.002 Mostert, 2011, Abandonment of treatment for childhood cancer: position statement of a SIOP PODC Working Group, Lancet Oncol, 12, 719, 10.1016/S1470-2045(11)70128-0 Van den Berg, 2008, Incidence of biopsy-proven bone tumors in children: a report based on the Dutch pathology registration “PALGA”, J Pediatr Orthop, 28, 29, 10.1097/BPO.0b013e3181558cb5 Raney, 1997, Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972 to 1991, J Clin Oncol, 15, 574, 10.1200/JCO.1997.15.2.574 Kennedy, 2000, Extraskeletal Ewing's sarcoma: a case report and review of the literature, Spine (PhilaPa 1976), 25, 1996, 10.1097/00007632-200008010-00022 Orr, 2012, Analysis of prognostic factors in extraosseous Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital experience, Ann Surg Oncol, 19, 3816, 10.1245/s10434-012-2458-4 Biswas, 2014, Evaluation of outcome and prognostic factors in extraosseous Ewing sarcoma, Pediatr Blood Cancer, 61, 1925, 10.1002/pbc.25095 Saiz, 2019, Role of radiation therapy in adult extraskeletal Ewing's sarcoma patients treated with chemotherapy and surgery, Sarcoma, 2019, 5413527, 10.1155/2019/5413527 Van den Berg, 2009, Extra-osseous Ewing sarcoma, Pediatr Hematol Oncol, 26, 175, 10.1080/08880010902855581 Takenaka, 2016, Treatment outcomes of Japanese patients with Ewing sarcoma: differences between skeletal and extraskeletal Ewing sarcoma, Jpn J Clin Oncol, 46, 522, 10.1093/jjco/hyw032 Galyfos, 2016, Extraosseous Ewing sarcoma: diagnosis, prognosis and optimal management, Indian J Surg, 78, 49, 10.1007/s12262-015-1399-0 Qureshi, 2013, Extraskeletal Ewing sarcoma in children and adolescents: impact of narrow but negative surgical margin, Pediatr Surg Int, 29, 1303, 10.1007/s00383-013-3409-2 Rud, 1989, Extraosseous Ewing's sarcoma. A study of 42 cases, Cancer, 64, 1548, 10.1002/1097-0142(19891001)64:7<1548::AID-CNCR2820640733>3.0.CO;2-W Covelli, 1980, Extraskeletal Ewing's sarcoma: prolonged survival with recurrence after operation, South Med J, 73, 1294, 10.1097/00007611-198009000-00053 Abboud, 2021, Extraskeletal Ewing Sarcoma : Diagnosis, management and prognosis, Oncol Lett., 21(5) Lee, 2010, Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry, Cancer, 116, 1964, 10.1002/cncr.24937 Honoki, 2007, Prognostic significance of p16 INK4a alteration for Ewing sarcoma: a meta-analysis, Cancer, 110, 1351, 10.1002/cncr.22908 Machado, 2014, Biomarkers in the Ewing sarcoma family of tumors, Curr Biomark Find, 4, 81, 10.2147/CBF.S40803 Jahromi, 2011, Copy number alterations and methylation in Ewing's Sarcoma, Sarcoma, 2011, 362173, 10.1155/2011/362173 Borowitz, 2008, Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study, Blood, 111, 5477, 10.1182/blood-2008-01-132837 Altman, 2012, Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration, PLoS Med, 9, e1001216, 10.1371/journal.pmed.1001216 Wang, 2011, The ups and downs of DNA repair biomarkers for PARP inhibitor therapies, Am J Cancer Res, 1, 301 Wang, 2012, The role of PARP1 in the DNA damage response and its application in tumor therapy, Front Med, 6, 156, 10.1007/s11684-012-0197-3 Tap, 2012, Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors, J Clin Oncol, 30, 1849, 10.1200/JCO.2011.37.2359 Olmos, 2010, Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study, Lancet Oncol, 11, 129, 10.1016/S1470-2045(09)70354-7 Olmos, 2010, Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside, Cancer J, 16, 183, 10.1097/PPO.0b013e3181dbebf9